[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"multiple-myeloma-or-plasmacytoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:multiple-myeloma-or-plasmacytoma":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":45,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100647234","phase-1-fapi-pet-imaging---an-exploratory-study-100647234",false,"NCT07705074","FAPI PET Imaging - An Exploratory Study","FAPI PET Imaging - a Multicentric Exploratory Evaluation","FAPIPET","Inclusion Criteria:\n\n* Written informed consent obtained and documented by the participant's signature.\n* Age ≥18 years at the time of consent.\n* Clinically established or suspected diagnosis or recurrence of an oncologic or non-oncologic disease as defined in chapter 7.1 of study protocol.\n* Availability of standard-of-care imaging (e.g., clinically established PET tracer or anatomical imaging such as CT\u002FMRI) to allow comparative evaluation.\n\nExclusion Criteria:\n\n* Severe claustrophobia that would preclude PET imaging.\n* Inability to remain still for the duration of the PET\u002FMR examination.\n* Current pregnancy or breastfeeding; no pregnancy test is required for women who are postmenopausal for ≥12 months or have undergone surgical sterilization, bilateral oophorectomy, or hysterectomy.\n* Previous hypersensitivity reactions to radiotracer administration\n* Inability to understand the study information, for example due to language barriers.\n* Subjects incapable of judgment (e.g. individuals under legal or medical incapacity).\n* Participants scheduled for PET\u002FMR imaging: Presence of MRI-incompatible metallic implants, electronic devices (e.g. pacemakers, cochlear implants), or other ferromagnetic foreign bodies.","ALL","18 Years",{"count":20,"type":21},770,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study is testing a new imaging tracer called \\[18F\\]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions like fibrosis and sarcoidosis.\n\n\\[18F\\]FAPI-74 attaches to a protein found on cells that are active in tumors and areas of scarring or inflammation. This may help doctors see these areas more clearly than with imaging methods used today, especially in diseases where current scans do not work well.\n\nPeople who join this study will get one injection of the tracer into a vein, then have one PET\u002FCT or PET\u002FMR scan. This takes about 2 hours in total. Researchers will compare the results with imaging the participant already had as part of their regular care, such as other PET scans, CT, or MRI. No extra treatment is given, and no other visits are needed.\n\nThe study will take place at 5 hospitals in Switzerland and plans to include about 770 adults with a confirmed or suspected diagnosis of one of the conditions being studied. The main goal is to see how clearly the tracer shows up on the scan. Researchers will also look at whether this new scan changes how confident doctors feel about a diagnosis, or changes the patient's treatment plan.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Thyroid Pathology","Head and Neck Cancer (H&N)","Sinonasal Tract Tumor","Sarcoidosis","Thyroid Cancer","Breast Cancer","Hepatocellular Carcinoma (HCC)","Gastric Cancer (GC)","Pancreatic Cancer, Adult","Urothelial Carcinoma (UC)","Multiple Myeloma or Plasmacytoma","Mesothelioma","Hepatic Fibrosis","Endometriosis (Diagnosis)","Lung Fibrosis","Neck Node Metastasis","Prostate Cancer (CRPC)",[46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61],"[18F]FAPI-74","Fibroblast Activation Protein","FAP-targeted imaging","PET\u002FCT","Radiotracer","Diagnostic imaging","Multicentric study","Radiopharmaceutical","FAPI","FAPI-74","nuclear medicine","University Hospital Zurich","swiss multicenter trial","Cancer-associated fibroblast imaging","oncologic imaging","non-oncologic imaging","NOT_YET_RECRUITING","2026-07-09",{"date":65,"type":66},"2026-07-15","ACTUAL",{"date":68,"type":21},"2026-08",{"date":70,"type":21},"2029-09",{"name":72,"class":73},"Martin Huellner","OTHER",5,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100549583","phase-1-engineered-dendritic-cell-vaccines-for-multiple-myeloma-100549583","NCT06435910","Engineered Dendritic Cell Vaccines for Multiple Myeloma","Engineered Dendritic Cell Vaccines for Remission Maintenance in Multiple Myeloma Patients","Inclusion Criteria:\n\n* Male and female subjects with multiple myeloma or plasmacytoma\n* Very good partial or complete remission (CR) after prior combination therapies.\n* Expected survival \\> 12 weeks\n* Adequate venous access for blood withdrawal or apheresis, and no other contraindications for blood withdrawal\n* Voluntary informed consent is given with willingness to continue follow up\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Uncontrolled active infection\n* HIV or active hepatitis B or hepatitis C infection\n* Concurrent use of systemic steroids; the use of inhaled steroids is not exclusionary","80 Years",{"count":84,"type":21},10,[24],"The purpose of this study is to determine the feasibility, safety, and efficacy of dendritic cell (DC) vaccines in the treatment of multiple myeloma (MM) or plasmacytoma based on immune-modified DC vaccines (DCvac). This approach is aimed to achieve prolonged maintenance of remission in multiple myeloma or plasmacytoma patients.",[38],[89,90,91],"MM","CAR T","DC vaccine","RECRUITING","2026-06-18",{"date":95,"type":66},"2026-06-23",{"date":97,"type":66},"2024-05-11",{"date":99,"type":21},"2027-12-31",{"name":101,"class":73},"Shenzhen Geno-Immune Medical Institute",1]